![Page 1: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/1.jpg)
Open Laboratory Drug Discovery at GSK: Collaborating on Medicines for Diseases of
the Developing World
Martin PanDiscovery Medicine
![Page 2: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/2.jpg)
Purpose of this Presentation
• GSK Commitment to Diseases of the Developing World
• Introduce the Tres Cantos open laboratory concept
• What does success look like?
![Page 3: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/3.jpg)
To improve the quality of human life
do morefeel betterlive longer
Our Mission
by enabling people to
![Page 4: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/4.jpg)
The Challenge
• Africa has 24% global disease burden, but only 3% of the world’s health workers
• Healthcare spending (annual per capita)– $34 - minimum required for
fundamental healthcare – <$12 - 35/46 countries in Africa
spend – $2,000 - high income countries
• Access to essential medicines– <30% - Africa
![Page 5: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/5.jpg)
GSK’s Response - Why?Ethical imperative
– Build a new, sustainable business model to address the needs and capabilities of the developing world
Image and reputation imperative
– Demonstrate to financial institutions & external stakeholders effective GSK management of non-financial risks and thereby meet the expectations of society
Business imperative
– Defend importance of IP framework for innovation
– Responsibly pursue commercial opportunitiesIt’s the right thing to do for patients, society
AND for our business
![Page 6: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/6.jpg)
GSK’s Contribution
Pre Clinical R&D
Pre Clinical R&D
Clinical R&D
Clinical R&D
New Business Models
New Business Models
Post LaunchPost
LaunchHealth SystemsHealth Systems
• R&D PPPs• Knowledge Pool• Open lab• Malaria screen• TB, malaria
• R&D PPPs• Knowledge Pool• APJEM R&D• Malaria vaccine• HIV
• Tiered pricing• Price caps• MIC Pricing• Branded generics• 5% return on malaria
vaccine• ViiV Healthcare• Brazil JV• AMC
• CME• Voluntary
licencing
• 20% reinvestment• LF elimination• African malaria
Partnership• PHASE• Positive Action and
PAFC• Humanitarian relief
![Page 7: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/7.jpg)
GSK, Tres Cantos, Spain
![Page 8: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/8.jpg)
• Focused on R&D in malaria, TB and other neglected diseases
• Collaborative with key funding partnerships
• Projects prioritised by unmet medical need - not commercial benefit
• Approx. 120 scientists in Tres Cantos• Full access to GSK resources
GSK Diseases of the Developing World
![Page 9: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/9.jpg)
What is our Vision for Tres Cantos?
• A campus that is recognised as a leading place to translate ideas into medicines for Diseases of the Developing World (DDW)
• The first port of call for any academic, institute or pharma company wishing to partner in drug discovery for DDW
• A pipeline of innovative transformational medicines for malaria, resistant TB and other Diseases of the Developing World
![Page 10: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/10.jpg)
January, 2010
![Page 11: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/11.jpg)
Open Innovation for Neglected Tropical Diseases
• Comprises three main strands:
– Being more flexible with our IP and know-how - Knowledge Pool
– Enabling access to our resources - open laboratory
– Opening up access to our compounds and data
![Page 12: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/12.jpg)
Current Antimalarial Therapy Covers a Very Limited Number of Biochemical Pathways
MitochondrionDrug:Atovaquone
Apicoplast
Drug:Azi, antibiotics
Food vacuole
Drug:4-aminoquinolines
Cytosol
Drug:Antifolates artemisinins
• Resitance emerging to all current classes of antimalarials
• Sequencing of P. falciparum genome has revealed more than 5000 genes
• Whole cell approach allows screening of all relevant blood-stage targets
• Assures a minimum of pharmacological requisites
• Membrane permeability
• Activity against target in its intracellular context
• Identification and validation of novel anti-malarial targets
Fidock, D.A. et al, Vol. 3, 2004, 509-520
![Page 13: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/13.jpg)
Data-sharing: Release of 13,500 Malaria Chemical Starting Points
• > 2 Million compound GSK corporate collection screened for inhibitors of malaria parasite growth– Whole cell approach under BSL3 containment– Year long effort involving multiple groups at GSK
• Over 13,500 hits identified – structures and data released on widely accessible internet sites
• Leadership step to engage worldwide scientists to fully exploit data and promote neglected disease research
• Jumpstart research on urgently needed novel antimalarial chemotypes and targets for drug discovery
13
![Page 14: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/14.jpg)
![Page 15: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/15.jpg)
EMBL-EBI Database for Mining Malaria Compound Setwww.ebi.ac.uk/chemblntd
![Page 16: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/16.jpg)
What is the Tres Cantos Open Lab?
• A concept intended to facilitate open collaboration between academia or other institutions and GSK
• An opportunity for external scientists to work alongside GSK drug discovery scientists in Tres Cantos
• A way for GSK to demonstrate commitment and seek new approaches for stimulating research in the field of neglected diseases
![Page 17: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/17.jpg)
General Principles of the Tres Cantos Open Lab
• Incoming projects will be aligned with our interests in TB, malaria or other neglected diseases
• Projects will benefit from the collaboration with DDW Drug Discovery
• An open approach to innovation in neglected diseases (intellectual property)
![Page 18: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/18.jpg)
Open Lab
Collaborations and Alliances
Governing Board
Chair of the Governing Board
DDW Campus Head
High-level Operating Model for the Tres Cantos Open Lab
![Page 19: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/19.jpg)
Tres Cantos Open Lab – `Open for Business´
• First open laboratory project has started; others being negotiated
• In the short-term, success for GSK will be that we have fostered the science and drug discovery in neglected diseases
• In the longer-term, success for GSK will be that we played our part in bringing transformational new medicines to people who need them
![Page 20: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/20.jpg)
Open Lab possibilities for TB?
![Page 21: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/21.jpg)
Open Architecture Approach to Research on Neglected Tropical Diseases
• Significant research funding devoted to neglected tropical diseases, but research largely fragmented
• Need for more concerted, collaborative approach to reduce redundancy and increase chance of success
• Neglected tropical disease research is an ideal area to explore innovative data sharing approaches
• Open architecture approach could be model for future pharmaceutical R&D
21
![Page 22: Stop TB Partnership - Working Group for New Drugs - Berlin 12Nov2010](https://reader036.vdocuments.site/reader036/viewer/2022062514/5584d902d8b42a25468b47d6/html5/thumbnails/22.jpg)
The over-arching priority ...
Focus on the Patient
The over-arching priority ...
Focus on the Patient